Ophthalmic Pharmaceutical Drugs - A Global Market Perspective

1.METHODOLOGY
Study Reliability and Reporting Limitations
Disclaimers
Quantitative Techniques & Reporting Level
2.INDUSTRY OVERVIEW
A Curtain Raiser
Drugs Developed in the Recent Past
What the Future Holds in Store?
Where Does the Opportunity Lie?
In the Shifting Demographics…
Which Disease Segment Offers Abundant Opportunities for R&D Initiatives
Leading Companies & Their Areas of Research Interest/Focus
Business Opportunities in Ophthalmology: A Fact Sheet
Impediments in Picking the Ripe & Low Hanging Opportunities
Low Patient Compliance
What’s the Antidote to Low Patient Compliance?
Innovation in Ophthalmic Pharmaceuticals: How Does It Help Patients?
An Unequivocal Discussion About Ocular Drug Design and Delivery
Why Understanding of the Metabolic Activity of the Eye is Important?
Pitfalls of Traditional Ocular Treatment
Ophthalmic Drug Delivery: A Recapitulation of Facts
Antidotes to Low Delivery of Ocular Drugs & High Side Effects
Prodrug
Soft Drugs (SDs)
Soft Corticosteroids
Drug Penetration Enhancers
Chitosan Based Drugs & Drug Delivery Systems
How Chitosan is used to Improve Ocular Drug Retention- On the Eye’s Surface?
The Future of Ophthalmic Drug Delivery
A Straight Talk About Ophthalmic Drug Delivery Technologies
High Flying Expectations of Blistering Pace of Drug Development- Grounded
First Generation Advancements Made in Ocular Drugs
Second Generation Advancements Made in Ocular Drugs
Limiting Factors
3.MARKET DYNAMICS
Ophthalmic Pharmaceuticals Poised to Encounter Days of Plenty…
Ophthalmic Inserts Flaunt the Potential to Eclipse the Popularity of Eye Drops
Rising Incidences of Glaucoma: A Business Case for Ophthalmic Drugs
Aging Population & Environmental Factors Drive Growth
Increase in Health Care Spending
Opportunities Abound in the Developing Countries
Innovative Products Lend Traction to Growth
Reimbursements: "Under the Umbrella"
4.PRODUCT FACTS
5.CORPORATE DEVELOPMENTS
Bausch & Lomb Acquires IOL Maker, Eyeonics
Akorn Inks Manufacture & Supply Agreement for Ophthalmic Solution
CrystalGenomics Enters Into R&D Agreement with Bausch & Lomb
Genaera Corporation Quits Evizon Clinical Trials
Eyetech Inc Divests Anti-Platelet Derived Growth Factor (PDGF) Aptamer- Program
Amneal, Indoco Agree to Develop & Market Generic Ophthalmic Drugs
Bausch & Lomb Acquire Soothe Products from Alimera
Froptix, Acuity, eXegenics Merge to Form Opko Corporation
Alimera, Emory Collaborate Over Potential Ophthalmic Treatments Using Novel Antioxidants
Santen Signs Agreement with Vistakon Pharmaceuticals for US Launch of Iquix®
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections
QLT Takes Over Forsight Newco II, Inc
Inspire Pharmaceuticals Rolls Out AzaSite™ for Ocular Infections
Novagali Obtains FDA Approval of Nova22007 IND for Ph III Trial
Alimera Conducts Phase III Medidur Trial
ISTA Pharmaceuticals Files NDA for Xibrom™ QD
AzaSite Receives FDA Approval
6.MAJOR PLAYERS
Akorn, Inc (USA)
Alcon Eye Care, Inc (USA)
Allergan, Inc. (USA)
Alimera Sciences, Inc (USA)
Bausch & Lomb, Inc (USA)
Genvec, Inc (USA)
Glaxosmithkline Plc (UK)
Inspire Pharmaceuticals, Inc (USA)
Ista Pharmaceuticals, Inc (USA)
Merck & Co., Inc (USA)
Opko Health, Inc (USA)
Otsuka Pharmaceutical Co., Ltd (JAPAN)
Pfizer Inc (USA)
QLT, Inc. (Canada)
Santen Pharmaceutical Co. (Japan)
Santen Inc. (US)
7.GLOBAL MARKET ANALYTICS
8.THE UNITED STATES
Emphasis on Greater Awareness About Ophthalmic Disorders
Growth Drivers In a Capsule
Impediments to Growth
Market Fact Sheet
Glaucoma Market: A Primer
Awareness Among Patients
High Costs
Treatment Patterns Adopted By Doctors
The All Consuming Issue of Compliance
Market Share Statistics
The New Batting Order
Update On Drugs & Their Manufacturers in the US
Patent Expirations of Key Ophthalmic Product Brands in the United States
Statistical Findings On Ophthalmic Diseases in the United States
9.CANADA
Lack of Awareness: A Key Issue
10.JAPAN
Growth Drivers
Market Data Statistics
11.EUROPE
a.France
b.Germany
c.The United Kingdom
d.Italy
e.Spain
f.Rest of Europe
12.ASIA-PACIFIC
13.LATIN AMERICA
14.REST OF WORLD
Table 1: Prevalence of Glaucoma in the World –2006 (In 000 Individuals)
Table 2: Global Ophthalmic Pharmaceutical Drugs Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 3: Percentage Breakdown of Global Ophthalmic Pharmaceutical Drugs Market by Region for the Years 2008 & 2009
Table 4: Global Glaucoma Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 5: Percentage Breakdown of Global Glaucoma Market by Region for the Years 2008 & 2009
Table 6: Global Anti-allergy Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 7: Percentage Breakdown of Global Anti-allergy Market by Region for the Years 2008 & 2009
Table 8: Global Anti-infective Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 9: Percentage Breakdown of Global Anti-infective Market by Region for the Years 2008 & 2009
Table 10: Global Dry Eye Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 11: Percentage Breakdown of Global Dry Eye Market by Region for the Years 2008 & 2009
Table 12: Global Anti-inflammation Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 13: Percentage Breakdown of Global Anti-inflammation Market by Region for the Years 2008 & 2009
Table 14: Global Back of Eye Market by Region for the Period 2007-2015 (Sales in US$ Million)
Table 15: Percentage Breakdown of Global Back of Eye Market by Region for the Years 2008 & 2012
Table 16: Global Other Treatment Category Market by Region for the Period 2007- 2015 (Sales in US$ Million)
Table 17: Percentage Breakdown of Global Other Treatment Category Market by Region for the Years 2008 & 2012
Table 18: Market Shares of Leading Players in the US Market for Ophthalmic Pharmaceutical Drugs – 2007E
Table 19: Breakdown of Top 10 Eye/ Lens Care Brands in the US –
Table 20: Breakdown of Top 5 Eye Care Products in the US –
Table 21: Market Shares of Leading Players in the US Age-Related Wet Macular Degeneration Market
Table 22: Market Shares of Leading Players in the US Ocular Allergy Market –2007E
Table 23: Market Shares of Leading Players in the US Market for Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) –
Table 24: Dollar Sales of Major Branded Drugs in the US Market for Age-Related Macular Degeneration - 2009 & 2012
Table 25: Prevalence of Age-Related Wet Macular Degeneration in the US – 2009 &
Table 26: Number of Individuals Treated for Wet AMD in the US- 2009 & 2012
Table 27: Prevalence of Ocular Hypertension (OHT) in the US- 2009 & 2012
Table 28: Prevalence of Primary Open Angle Glaucoma (POAG) in the US - 2009 & 2012
Table 29: Prevalence of Normal Tension Glaucoma (NTG) in the US - 2009 &
Table 30: Prevalence of Exfoliative Glaucoma (EG) in the United States for the Years 2009 & 2011 (In Thousand Individuals)
Table 31: Prevalence of Pigmentary Glaucoma (PG) in the United States for the Years 2009 & 2011 (In Thousand Individuals)
Table 32 Breakdown of Number of Individuals Treated for Glaucoma by Type in the United Sates - 2009 and 2011 (In 000 Individuals)
Table 33: Prevalence of Ocular Allergy in the United States for the Years 2009 & 2012 (In Millions of Individuals)
Table 34: Number of Individuals Treated for Ocular Allergy in the United States - 2009 &
Table 35: Prevalence of Cataract in the US – 2009 & 2012
Table 36: Number of Individuals Treated for Cataract With Ocular NSAIDs (Topical Non-Steroidal Anti-Inflammatory Drugs) in the US - 2009 & 2012
Table 37: Prevalence of Dry Eye in the US – 2009 & 2012
Table 38: Number of Individuals Treated for Dry Eye in the US - 2009 & 2012
Table 39: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in the US: 2007-2015 (Sales in US$ Million)
Table 40: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in the US for the Years 2008 & 2012
Table 41: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Canada: 2007-2015 (Sales in US$ Million)
Table 42: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Canada for the Years 2008 & 2012
Table 43: Percentage Breakdown of Japanese Market for Prescription Ophthalmic Drugs by Therapeutic Area –
Table 44: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Japan: 2007-2015 (Sales in US$ Million)
Table 45: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Japan for the Years 2008 & 2012
Table 46: Ophthalmic Pharmaceutical Drugs Market by Region in Europe: 2007-2015 (Sales in US$ Million)
Table 47: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Region in Europe for the Years 2008 & 2012
Table 48: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Europe: 2007-2015 (Sales in US$ Million)
Table 49: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Europe for the Years 2008 & 2012
Table 50: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in France: 2007-2015 (Sales in US$ Million)
Table 51: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in France for the Years 2008 & 2012
Table 52: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Germany: 2007-2015 (Sales in US$ Million)
Table 53: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Germany for the Years 2008 & 2012
Table 54: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in the UK: 2007-2015 (Sales in US$ Million)
Table 55: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in the UK for the Years 2008 & 2012
Table 56: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Italy: 2007-2015 (Sales in US$ Million)
Table 57: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Italy for the Years 2008 & 2012
Table 58: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Spain: 2007-2015 (Sales in US$ Million)
Table 59: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Spain for the Years 2008 & 2012
Table 60: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of Europe: 2007-2015 (Sales in US$ Million)
Table 61: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of Europe for the Years 2008 & 2012
Table 62: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Asia-Pacific: 2007-2015 (Sales in US$ Million)
Table 63: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Asia-Pacific for the Years 2008 & 2012
Table 64: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Latin America: 2007-2015 (Sales in US$ Million)
Table 65: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Latin America for the Years 2008 & 2012
Table 66: Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of World: 2007-2015 (Sales in US$ Million)
Table 67: Percentage Breakdown of Ophthalmic Pharmaceutical Drugs Market by Therapeutic Category in Rest of World for the Years 2008 & 2012
Companies Profiled